Trial intelligence / Profile preview

MESH: Methotrexate in MSH2-deficient metastatic colorectal cancer

2008-000524-82Phase 2Terminated

Sponsor: Royal Marsden NHS Foundation Trust
Start: Dec 2010
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, open-label, single-arm trial of methotrexate in colorectal cancer (CRC), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: Objective response rate by RECIST. Started Dec 2010; status: terminated.

Drugs

methotrexate

Conditions

colorectal cancer (CRC)

Beyond the preview

Go deeper on 2008-000524-82.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2008-000524-82.